Digest Network Come funziona
Network
/
Società
An
Non verificato

Ankyra Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
15/12/2025
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
17/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
04/11/2025
Scienza
Veterinaria
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
05/11/2024
Industria
Oncologia
Salute
Medicina - Varie
Medicina nucleare
Farmaceutica
Biotecnologia
Ankyra Therapeutics Announces First Visceral Tumor Patient Dosed in Phase 1 ANCHOR Clinical Trial of ANK-101, an Anchored Interleukin-12 (IL-12)
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
23/09/2024
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
04/10/2023
Accessori
Vetrine/Shopping
Management
Medicina - Varie
Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0